Personalize My Medicine
Personalize My Medicine works to help bridge the information gap between the explosion in medical innovations and the researchers, doctors, and patients who want to apply this information to their work and life, thus placing patients at the center of medical advancements. The goal of Personalize My Medicine is to solve this problem by creating a patient-centered medicine approach, in which patients have better access to innovations and actively participate in making them available.
Condition Awareness & Advocacy
Here is a list of conditions this partner raises awareness and advocacy for:
Patient Worthy Posts on Rare Disease and Medication
Affinia Therapeutics Secures FDA Orphan Drug Designation for Investigational BAG3 Cardiomyopathy Gene Therapy
As reported on Pharmaceutical Business Review, Affinia Therapeutics has been granted orphan drug designation by the US Food and Drug Administration (FDA) for AFTX-201, an
FDA Authorization Positions Johnson & Johnson to Enter Competitive Surgical Robotics Market
As reported on Fierce BioTech, Johnson & Johnson has received U.S. Food and Drug Administration (FDA) clearance for its Ottava Robotic Surgical System, marking a
Scientists Find Poly-coated Nanoparticles Plus Therapeutic Drugs Have a Potential as Cancer Treatment
As reported on Science Daily, scientists have combined polymer-coated nanoparticles with therapeutic drugs for cancer treatment, including treatment for ovarian cancer. The nanoparticles target tumors
Cincinnati Children’s Becomes Seventh U.S. Center Authorized to Deliver ZEVASKYN for RDEB Patients
As reported by The Manila Times, Abeona Therapeutics has announced that Cincinnati Children’s Hospital Medical Center has been designated as the seventh Qualified Treatment Center
Xeltis Launches aXess™ Hemodialysis Device in Europe Following First Commercial Implant
Medical device innovator Xeltis has officially kicked off the European commercial rollout of its novel vascular access implant, aXess™. The milestone was marked by the
FDA Investigating Death of Two Young Duchenne Muscular Dystrophy Patients Due to Acute Liver Failure
The FDA has Completed Its Investigation of the Recent 2024 Deaths of Two Young Boys Due to Liver Failure. Acute failure of the liver has
